BIODESIX INC (BDSX) Stock Overview
USA - NASDAQ:BDSX - US09075X1081 - Common Stock
BDSX Key Statistics, Chart & Performance
The current stock price of BDSX is 7.13 USD. In the past month the price decreased by -17.95%. In the past year, price decreased by -81.31%.
BDSX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.82 | 95.02B | ||
| CI | THE CIGNA GROUP | 10.34 | 77.51B | ||
| LH | LABCORP HOLDINGS INC | 18.31 | 23.04B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.41 | 20.53B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 127.16 | 16.67B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 12.28 | 14.85B | ||
| HIMS | HIMS & HERS HEALTH INC | 72.27 | 13.07B | ||
| DVA | DAVITA INC | 13.43 | 9.31B | ||
| GH | GUARDANT HEALTH INC | N/A | 7.38B | ||
| CHE | CHEMED CORP | 20.22 | 6.59B | ||
| RDNT | RADNET INC | 212.33 | 5.88B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 36.89 | 4.84B |
Related stock screener links
About BDSX
Company Profile
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Company Info
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 273
Phone: 13034170500
BIODESIX INC / BDSX FAQ
What is the stock price of BIODESIX INC today?
The current stock price of BDSX is 7.13 USD. The price increased by 5.94% in the last trading session.
What is the ticker symbol for BIODESIX INC stock?
The exchange symbol of BIODESIX INC is BDSX and it is listed on the Nasdaq exchange.
On which exchange is BDSX stock listed?
BDSX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIODESIX INC stock?
11 analysts have analysed BDSX and the average price target is 1.79 USD. This implies a price decrease of -74.96% is expected in the next year compared to the current price of 7.13. Check the BIODESIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIODESIX INC worth?
BIODESIX INC (BDSX) has a market capitalization of 1.05B USD. This makes BDSX a Small Cap stock.
How many employees does BIODESIX INC have?
BIODESIX INC (BDSX) currently has 273 employees.
What are the support and resistance levels for BIODESIX INC (BDSX) stock?
BIODESIX INC (BDSX) has a support level at 6.2 and a resistance level at 7.85. Check the full technical report for a detailed analysis of BDSX support and resistance levels.
Is BIODESIX INC (BDSX) expected to grow?
The Revenue of BIODESIX INC (BDSX) is expected to grow by 17.45% in the next year. Check the estimates tab for more information on the BDSX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIODESIX INC (BDSX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BDSX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BDSX, evaluating the profitability, health, valuation and growth aspects
- BIODESIX INC (BDSX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIODESIX INC (BDSX) Sales and EPS estimates to see what analysts future expectations are.
- BIODESIX INC (BDSX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIODESIX INC (BDSX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIODESIX INC (BDSX) Stock Chart to make your own analysis
- BIODESIX INC (BDSX) Latest news and press-releases to stay up to date.
Does BIODESIX INC (BDSX) stock pay dividends?
BDSX does not pay a dividend.
When does BIODESIX INC (BDSX) report earnings?
BIODESIX INC (BDSX) will report earnings on 2025-10-30, after the market close.
What is the Price/Earnings (PE) ratio of BIODESIX INC (BDSX)?
BIODESIX INC (BDSX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).
BDSX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX is a bad performer in the overall market: 92.55% of all stocks are doing better.
BDSX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BDSX. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative.
BDSX Financial Highlights
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 36.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.82% | ||
| ROE | -3609.67% | ||
| Debt/Equity | 41.11 |
BDSX Forecast & Estimates
11 analysts have analysed BDSX and the average price target is 1.79 USD. This implies a price decrease of -74.96% is expected in the next year compared to the current price of 7.13.
For the next year, analysts expect an EPS growth of 17.67% and a revenue growth 17.45% for BDSX